Emicizumab’s Effect on the PTT

Here is an informative December 2020 CAP Today article, “Digging Into Drug’s Effect on aPTT-based Assays” [click] by staff writer Amy Carpenter Aquino. The article documents a CAP20 hemophilia therapy session, “aPTT assays in patients on emicizumab are not going to be accurate. And the effect of the drug on our aPTT-based assays can last up to six months following discontinuation of that medication” by Andrew J. Goodwin, MD, clinical pathology division chief and CLIA director, University of Vermont Medical Center and David Unold, MD, associate medical director, transfusion services, University of California Davis Medical Center.